Nanexa

Lepu Medical's Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World's First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia
CompanyDrug

Lepu Medical’s Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World’s First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia

Lepu Medical Technology (Beijing) Co., Ltd. (SHE: 300003) announced that MWX205 Injection, a dual‑target small interfering RNA (siRNA) drug independently developed by its controlled subsidiary Shanghai Minwei Biotechnology Co., Ltd.…

IASO Bio's In Vivo CAR‑T IASO208 Clears NMPA IND – CD20‑Targeting Therapy Heads to Phase Ib in the US for R/R B‑NHL

IASO Bio’s In Vivo CAR‑T IASO208 Clears NMPA IND – CD20‑Targeting Therapy Heads to Phase Ib in the US for R/R B‑NHL

AstraZeneca Acquires Omniose – Vaccine Bioconjugation Specialist Bolsters Bacterial Threat Defense Within Infectious Disease Unit

AstraZeneca Acquires Omniose – Vaccine Bioconjugation Specialist Bolsters Bacterial Threat Defense Within Infectious Disease Unit

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Novo Nordisk Licenses Nanexa's PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes
CompanyDeals

Novo Nordisk Licenses Nanexa’s PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes